These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 1758533)
1. Osteocalcin levels in uremic patients: influence of calcitriol treatment through two different routes and type of dialysis. Martinez ME; Selgas R; Miguel JL; Balaguer G; Sanchez-Cabezudo MJ; Llach F Nephron; 1991; 59(3):429-33. PubMed ID: 1758533 [TBL] [Abstract][Full Text] [Related]
2. Effect of CAPD and hemodialysis on parathyroid function. Malberti F; Corradi B; Imbasciati E Adv Perit Dial; 1996; 12():239-44. PubMed ID: 8865912 [TBL] [Abstract][Full Text] [Related]
3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
4. Long-term effect of oral calcitriol single weekly pulse in CAPD and in HD. Romanini D; Gazo A; Bellazzi R; de Vincenzi A; Nai M; Santagostino M Adv Perit Dial; 1994; 10():267-9. PubMed ID: 7999842 [TBL] [Abstract][Full Text] [Related]
5. Effects of subcutaneous calcitriol administration on plasma calcium and parathyroid hormone concentrations in continuous ambulatory peritoneal dialysis uremic patients. Rolla D; Paoletti E; Marsano L; Mulas D; Peloso G; Cannella G Perit Dial Int; 1993; 13(2):118-21. PubMed ID: 8494932 [TBL] [Abstract][Full Text] [Related]
6. Does calcitriol therapy improve muscle function in uremic patients. Wanic-Kossowska M; Grzegorzewska A; Plotast H; Bombicki K Perit Dial Int; 1996; 16 Suppl 1():S305-8. PubMed ID: 8728212 [TBL] [Abstract][Full Text] [Related]
7. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients. Lee SH; Huang TS; Hsieh SJ Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625 [TBL] [Abstract][Full Text] [Related]
8. Differences in calcium kinetic pattern between CAPD and HD patients. Kurz P; Tsobanelis T; Roth P; Werner E; Ewald U; Grützmacher P; Schoeppe W; Vlachojannis J Clin Nephrol; 1995 Oct; 44(4):255-61. PubMed ID: 8575126 [TBL] [Abstract][Full Text] [Related]
9. The determination of insulin sensitivity in hemodialysis and continuous ambulatory peritoneal dialysis in nondiabetic patients with end-stage renal disease. Tuzcu A; Bahceci M; Yilmaz ME; Turgut C; Kara IH Saudi Med J; 2005 May; 26(5):786-91. PubMed ID: 15951871 [TBL] [Abstract][Full Text] [Related]
10. Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose. Heimbürger O; Stenvinkel P; Berglund L; Tranoeus A; Lindholm B Nephron; 1996; 72(2):135-44. PubMed ID: 8684516 [TBL] [Abstract][Full Text] [Related]
11. The sigmoidal parathyroid hormone-ionized calcium curve and the set point of calcium in hemodialysis and continuous ambulatory peritoneal dialysis. Malberti F; Corradi B; Pagliari B; Romanini D; Gazo A; Sidoti A; Baretta A; Bellazzi R; Imbasciati E Perit Dial Int; 1993; 13 Suppl 2():S476-9. PubMed ID: 8399645 [TBL] [Abstract][Full Text] [Related]
12. Histamine and serotonin in uremic pruritus: effect of ondansetron in CAPD-pruritic patients. Balaskas EV; Bamihas GI; Karamouzis M; Voyiatzis G; Tourkantonis A Nephron; 1998; 78(4):395-402. PubMed ID: 9578065 [TBL] [Abstract][Full Text] [Related]
13. Serum and erythrocyte tocopherol in uremic patients: effect of hemodialysis versus peritoneal dialysis. Pastor MC; Sierra C; Bonal J; Teixidó J Am J Nephrol; 1993; 13(4):238-43. PubMed ID: 8267019 [TBL] [Abstract][Full Text] [Related]
14. Evidence for preservation of cortical bone mineral density in patients on continuous ambulatory peritoneal dialysis. Mottet JJ; Horber FF; Casez JP; Descoeudres C; Jaeger P J Bone Miner Res; 1996 Jan; 11(1):96-104. PubMed ID: 8770702 [TBL] [Abstract][Full Text] [Related]
15. A randomized trial comparing 1.25 mmol/l calcium dialysate to 1.75 mmol/l calcium dialysate in CAPD patients. Johnson DW; Rigby RJ; McIntyre HD; Brown A; Freeman J Nephrol Dial Transplant; 1996 Jan; 11(1):88-93. PubMed ID: 8649658 [TBL] [Abstract][Full Text] [Related]
16. Uremic myopathy and calcitriol therapy in CAPD patients. Bertoli M; Luisetto G; Arcuti V; Urso M ASAIO Trans; 1991; 37(3):M397-8. PubMed ID: 1751206 [TBL] [Abstract][Full Text] [Related]
17. Comparison of the humoral markers of bone turnover and bone mineral density in patients on haemodialysis and continuous ambulatory peritoneal dialysis. Hampson G; Vaja S; Evans C; Chesters CA; Pettit R; Evans W; Thomas D; Seed PT; Fraser WD Nephron; 2002 May; 91(1):94-102. PubMed ID: 12021525 [TBL] [Abstract][Full Text] [Related]
18. Bone mineral density and bone metabolism are not related to leptin in hemodialyzed and peritoneally dialyzed uremic patients. Małyszko J; Małyszko JS; Bondyra Z; Wołczyński S; Łebkowska U; Myśliwiec M Med Sci Monit; 2004 Jun; 10 Suppl 3():115-9. PubMed ID: 16538212 [TBL] [Abstract][Full Text] [Related]
19. Hyperparathyroidism in CAPD patients: therapy with pulse oral calcitriol. Juergensen PH; Finkelstein FO; Cooper K; Santacroce S; Kliger AS Adv Perit Dial; 1993; 9():257-9. PubMed ID: 8105938 [TBL] [Abstract][Full Text] [Related]
20. Low calcium (1.25 mmol/L) dialysate can normalize relative hypoparathyroidism in CAPD patients with low bone turnover. Shigematsu T; Kawaguchi Y; Kubo H; Nakayama M; Kato N; Yamamoto H; Osaka N; Hayakawa H; Ogawa A; Sakai O Adv Perit Dial; 1996; 12():250-6. PubMed ID: 8865914 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]